OverviewSuggest Edit

Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.

The goal at Impel is simple: we want to develop the next generation of therapeutics for central nervous system (CNS) disorders. Patients with CNS disorders are vastly underserved by current therapeutics and we are working hard to change that. Impel has built the POD drug delivery platform to allow entire classes of molecules to reach the brain that never could before. Impel has expanded its scope to both partnership with pharmaceutical companies and the development of our own drug products compatible with the POD platform. We take a comprehensive approach to development and design considering patient comfort, regulatory approval pathways, and cost effectiveness. Treatments currently under development include therapies for migraine, Alzheimer’s disease, Parkinson’s disease, and pain relief

TypePrivate
Founded2008
HQSeattle, US
Websiteimpelnp.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Mar 2019)49(+9%)

Key People/Management at Impel NeuroPharma

John Hoekman

John Hoekman

Co-Founder and CSO, Co-Founder and CSO
Jon Congleton

Jon Congleton

President & CEO, President & CEO
Stephen Shrewsbury

Stephen Shrewsbury

Chief Medical Officer
Ellen Lubman

Ellen Lubman

Chief Business Officer
Lynn Gold

Lynn Gold

Senior VP of Regulatory
Michael Malafronte

Michael Malafronte

VP of Quality Assurance
Show more

Impel NeuroPharma Office Locations

Impel NeuroPharma has an office in Seattle
Seattle, US (HQ)
915 E Pine St
Show all (1)
Report incorrect company information

Impel NeuroPharma Financials and Metrics

Summary Metrics

Founding Date

2008

Impel NeuroPharma total Funding

$108.1 m

Impel NeuroPharma latest funding size

$67.50 m

Time since last funding

3 months ago

Impel NeuroPharma investors

Impel NeuroPharma's latest funding round in December 2018 was reported to be $67.5 m. In total, Impel NeuroPharma has raised $108.1 m
View all funding rounds
Report incorrect company information

Impel NeuroPharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Impel NeuroPharma News and Updates

Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

SEATTLE, Jan. 6, 2019 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on innovative therapies for the treatment of central nervous system (CNS) disorders, today announced positive results of a Phase 1 trial of INP105. INP105 is a...

Impel NeuroPharma Closes $67.5 Million Series D Financing

SEATTLE, Dec. 6, 2018 /PRNewswire/ -- Impel NeuroPharma ("Impel" or the "Company"), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has...
Report incorrect company information

Impel NeuroPharma Blogs

Placebo/Active Controlled, Safety, Pharmaco-Kinetic/Dynamic Study of INP105 (POD olanzapine) in Healthy Adults

March 2019 - A 2008 survey of emergency department staff (ED) found that 65% had witnessed physical attacks, 32% reported at least one verbal threat per day, and 18% had been assaulted at least once with a weapon. While many of the attacks were due to acute agitation, only 6% of the surveyed EDs had…

Development of a Precision Olfactory Delivery (POD)-Olanzapine Drug-Device Product for Agitation

March 2019 - Agitation is a cluster of behaviors observed in multiple psychiatric diseases, which can increase the likelihood of violent behavior. Atypical antipsychotics, including oral and intramuscular (IM) olanzapine (OLZ), have been approved for chronic and acute agitation treatment, respective…

Cowen 39th Annual Health Care Conference

The Impel team will be presenting at the Cowen 39th Annual Health Care Conference on March 11 - 13, 2019 in Boston, MA. Our CEO, Jon Congleton will be presenting and our CBO, Ellen Lubman will also attend.

Impel NeuroPharma Appoints Jennifer L. Berman as Vice President of Marketing

Significant Leadership Experience in CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization. Impel NeuroPharma today announced that Jennifer L. Berman has joined the Company as the Vice President of Marketing.

STOP 101: A Phase 1, Randomized, Open‐Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in Healthy Adult Subjects

INP104 met the predefined statistical criteria for comparative bioavailability with IV DHE and Migranal. The shorter time to reach Cmax and at 4 times the plasma concentration of DHE in comparison to Migranal combined with a favorable tolerability profile support further investigation of INP104 as a…

37th Annual J.P. Morgan Healthcare Conference – 7 JAN

The Impel team will be attending the 37th Annual J.P. Morgan Healthcare Conference on January 7 – 10, 2019 at the Westin St. Francis Hotel in San Francisco, CA. For more information, visit the event page here.
Show more

Impel NeuroPharma Frequently Asked Questions

  • When was Impel NeuroPharma founded?

    Impel NeuroPharma was founded in 2008.

  • Who are Impel NeuroPharma key executives?

    Impel NeuroPharma's key executives are John Hoekman, Jon Congleton and Stephen Shrewsbury.

  • How many employees does Impel NeuroPharma have?

    Impel NeuroPharma has 49 employees.

  • Who are Impel NeuroPharma competitors?

    Competitors of Impel NeuroPharma include Pressure BioSciences, K2M Group and ResMed.

  • Where is Impel NeuroPharma headquarters?

    Impel NeuroPharma headquarters is located at 915 E Pine St, Seattle.

  • Where are Impel NeuroPharma offices?

    Impel NeuroPharma has an office in Seattle.

  • How many offices does Impel NeuroPharma have?

    Impel NeuroPharma has 1 office.